Fig. 7: Anti-proliferative effect of proteolysis-targeting chimeras (PROTACs) using 6-position-modified lenalidomides on diverse cancer cell lines.

a Dose–response curves of anti-proliferative effects of PROTACs on MM cell lines. MM1.S and H929 cells were treated with dimethylsulfoxide (DMSO), PROTACs, or OTX-015 for 5 days, and cell viability was analysed using the CellTiter-Glo assay kit. Cell viability was expressed as the luminescence signal relative to the luminescence signal of DMSO, which was considered 100. Error bars denote standard deviation (biological replicates; n = 4). b Degradation of BET proteins by PROTACs in a neuroblastoma cell line. IMR32 cells were treated with DMSO or PROTACs for 24 h. The experiment was independently repeated thrice, with similar results. c Dose–response curves of anti-proliferative effects of PROTACs on the neuroblastoma cell line. IMR32 cells were treated with DMSO, PROTAC, or OTX-015 for 4 days, and cell viability was analysed using the CellTiter-Glo assay kit. Cell viability was expressed as the luminescence signal relative to the luminescence signal of DMSO, which was considered 100. Error bars denote standard deviation (biological replicates; n = 4). d Degradation of BET proteins by PROTACs in a colon cancer cell line. HCT116 cells were treated with DMSO or PROTACs for 24 h. The experiment was independently repeated thrice, with similar results. e Dose–response curves of anti-proliferative effects of PROTACs on a colon cancer cell line. HCT116 cells were treated with DMSO, PROTACs, or OTX-015 for 4 days, and cell viability was analysed using the CellTiter-Glo assay kit. Cell viability was expressed as the luminescence signal relative to the luminescence signal of DMSO, which was considered 100. Error bars denote standard deviation (biological replicates; n = 4). f The half-maximal growth inhibition (GI₅₀) and the maximal growth inhibition (GI_max) values were calculated using dose–response curves in (a, c, e). Source data are provided as a Source data file.